Literature DB >> 14686491

Rituximab treatment for relapsed autoimmune hemolytic anemia in Evans syndrome.

Anat Galor1, Timothy O'Brien.   

Abstract

A case is reported of idiopathic relapsed autoimmune hemolytic anemia successfully treated with rituximab. A 43-year-old white male patient with past medical history of Evans syndrome was found to have recurrent autoimmune hemolytic anemia. Previous treatments included steroids, splenectomy, intravenous immunoglobulin, plasmapheresis, staphylococcal Protein A immunoadsorption (Prosorba column), and chemotherapeutic agents (cytoxan and vincristine). Rituximab was given weekly at 375 mg/m2 for 4 doses. The drug was well tolerated and the patient remains in remission 9 months after completion of therapy.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 14686491     DOI： 10.1007/BF02983558

Source DB:  PubMed          Journal:  Int J Hematol        ISSN： 0925-5710            Impact factor:   2.490


  10 in total

1.  Sustained complete remission of chronic refractory immune thrombocytopenic purpura (ITP) of 10 years duration after only two infusions of rituximab.

Authors:  Yossi Cohen; Aaron Polliack
Journal:  Hematol J       Date:  2002

2.  Rituximab for refractory childhood autoimmune hemolytic anemia.

Authors:  David G Motto; James A Williams; Laurence A Boxer
Journal:  Isr Med Assoc J       Date:  2002-11       Impact factor: 0.892

3.  IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma.

Authors:  D G Maloney; A J Grillo-López; C A White; D Bodkin; R J Schilder; J A Neidhart; N Janakiraman; K A Foon; T M Liles; B K Dallaire; K Wey; I Royston; T Davis; R Levy
Journal:  Blood       Date:  1997-09-15       Impact factor: 22.113

4.  Effective treatment with rituximab in a patient with refractory prolymphocytoid transformed B-chronic lymphocytic leukemia and Evans syndrome.

Authors:  G Seipelt; A Böhme; S Koschmieder; D Hoelzer
Journal:  Ann Hematol       Date:  2001-03       Impact factor: 3.673

5.  Anti-CD20 monoclonal antibody (Rituximab) for life-threatening autoimmune haemolytic anaemia in a patient with systemic lupus erythematosus.

Authors:  Silverio Perrotta; Franco Locatelli; Angela La Manna; Lucia Cennamo; Piero De Stefano; Bruno Nobili
Journal:  Br J Haematol       Date:  2002-02       Impact factor: 6.998

6.  Monotherapy with rituximab induces rapid remission of recurrent cold agglutinin-mediated hemolytic anemia in a patient with indolent lympho-plasmacytic lymphoma.

Authors:  Y Cohen; A Polliack; O Zelig; A Goldfarb
Journal:  Leuk Lymphoma       Date:  2001 Nov-Dec

7.  A pilot study of the anti-CD20 monoclonal antibody rituximab in patients with refractory immune thrombocytopenia.

Authors:  M N Saleh; J Gutheil; M Moore; P W Bunch; J Butler; L Kunkel; A J Grillo-López; A F LoBuglio
Journal:  Semin Oncol       Date:  2000-12       Impact factor: 4.929

8.  Rituximab for the treatment of refractory autoimmune hemolytic anemia in children.

Authors:  Marco Zecca; Bruno Nobili; Ugo Ramenghi; Silverio Perrotta; Giovanni Amendola; Pasquale Rosito; Momcilo Jankovic; Paolo Pierani; Piero De Stefano; Mario Regazzi Bonora; Franco Locatelli
Journal:  Blood       Date:  2003-01-16       Impact factor: 22.113

9.  Beneficial effects of rituximab on primary cold agglutinin disease refractory to conventional therapy.

Authors:  Akinori Mori; Jun-Ichi Tamaru; Hajime Sumi; Haruki Kondo
Journal:  Eur J Haematol       Date:  2002-04       Impact factor: 2.997

10.  Rituximab-based chemotherapy for steroid-refractory autoimmune hemolytic anemia of chronic lymphocytic leukemia.

Authors:  N Gupta; S Kavuru; D Patel; D Janson; N Driscoll; S Ahmed; K R Rai
Journal:  Leukemia       Date:  2002-10       Impact factor: 11.528
  10 in total
  6 in total

Review 1.  Diagnosis and treatment of autoimmune haemolytic anaemias in adults: a clinical review.

Authors:  Peter Valent; Klaus Lechner
Journal:  Wien Klin Wochenschr       Date:  2008       Impact factor: 1.704

Review 2.  Rituximab in the treatment of autoimmune haemolytic anaemia.

Authors:  Chaturaka Rodrigo; Senaka Rajapakse; Lallindra Gooneratne
Journal:  Br J Clin Pharmacol       Date:  2015-05       Impact factor: 4.335

3.  Evans syndrome following long-standing Hashimoto's thyroiditis and successful treatment with rituximab.

Authors:  Hye Jin Oh; Myung Jae Yun; Seong Tae Lee; Seung June Lee; So Yeon Oh; In Sohn
Journal:  Korean J Hematol       Date:  2011-12-27

4.  Successful treatment with cyclosporine and high-dose gamma immunoglobulin for persistent parvovirus B19 infection in a patient with refractory autoimmune hemolytic anemia.

Authors:  Shigeki Ito; Tatsuo Oyake; Toshiyuki Uchiyama; Takeshi Sugawara; Kazunori Murai; Yoji Ishida
Journal:  Int J Hematol       Date:  2004-10       Impact factor: 2.490

5.  Rituximab therapy in a patient with autoimmune hemolytic anemia and immune thrombocytopenia associated with chronic lymphocytic leukemia.

Authors:  Aamer Aleem
Journal:  Ann Saudi Med       Date:  2008 Sep-Oct       Impact factor: 1.526

Review 6.  Evans syndrome: clinical perspectives, biological insights and treatment modalities.

Authors:  José Carlos Jaime-Pérez; Patrizia Elva Aguilar-Calderón; Lorena Salazar-Cavazos; David Gómez-Almaguer
Journal:  J Blood Med       Date:  2018-10-10
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.